Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Mogg

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
JAMA Oncology|July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical TrialsIgor Puzanov, Antoni Ribas, Caroline Robert, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 8, 2022
End-point definition and trial design to advance tuberculosis vaccine developmentAlberto L Garcia-Basteiro, Richard G White, Dereck Tait, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 9, 2006
Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and CameroonSwati B Gupta, Christopher T Mast, Nathan D Wolfe, et al.
Cancer Medicine|December 8, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancerDavid G Pfister, Robert I Haddad, Francis P Worden, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 25, 2008
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adultsFrances H Priddy, Deborah Brown, James Kublin, et al.
Science (New York, N.Y.)|October 13, 2018
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapyRazvan Cristescu, Robin Mogg, Mark Ayers, et al.
The Lancet. HIV|October 14, 2022
Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panelMaurine D Miner, Mark Hatherill, Vidya Mave, et al.
Nature Medicine|February 27, 2019
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanomaAlexander C Huang, Robert J Orlowski, Xiaowei Xu, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
JAMA Oncology|July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical TrialsIgor Puzanov, Antoni Ribas, Caroline Robert, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 8, 2022
End-point definition and trial design to advance tuberculosis vaccine developmentAlberto L Garcia-Basteiro, Richard G White, Dereck Tait, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 9, 2006
Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and CameroonSwati B Gupta, Christopher T Mast, Nathan D Wolfe, et al.
Cancer Medicine|December 8, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancerDavid G Pfister, Robert I Haddad, Francis P Worden, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 25, 2008
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adultsFrances H Priddy, Deborah Brown, James Kublin, et al.
Science (New York, N.Y.)|October 13, 2018
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapyRazvan Cristescu, Robin Mogg, Mark Ayers, et al.
The Lancet. HIV|October 14, 2022
Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panelMaurine D Miner, Mark Hatherill, Vidya Mave, et al.
Nature Medicine|February 27, 2019
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanomaAlexander C Huang, Robert J Orlowski, Xiaowei Xu, et al.
Pageof 4